Trump admin is “destroying medical research,” Senate report finds

During a recent hearing held by the Senate Committee on Health, Education, Labor, and Pensions (HELP), Jay Bhattacharya, who led the National Institutes of Health (NIH) under the Trump administration, faced scrutiny regarding significant cuts to medical research funding. In his testimony, Bhattacharya defended the controversial decisions made during his tenure, particularly in relation to vaccines, while navigating the political sensitivities surrounding his boss, Health Secretary Robert F. Kennedy Jr., known for his anti-vaccine stance. As Bhattacharya spoke, Senator Bernie Sanders (I-Vt.), the ranking member of the HELP committee, released a report that painted a grim picture of the NIH's current state. This report asserted that the Trump administration was not only "failing American patients" but was also actively "destroying medical research" through substantial cuts to research grants and the termination of clinical trials. The findings revealed that since Trump assumed office, the NIH had frozen or terminated hundreds of millions of dollars in research funding. Notably, the report highlighted the loss of $561 million in grants aimed at investigating the top four causes of death in the United States. Specific areas impacted included cancer research, where 116 grants totaling $273 million were affected, heart disease studies with 71 grants amounting to $111 million, Alzheimer’s research with 65 grants worth $94 million, and diabetes research with 68 grants totaling $83 million. Moreover, the report indicated that at least 304 clinical trials had been defunded, including 69 targeting pediatric patients. Senators expressed deep concerns during the hearing, emphasizing how these funding cuts jeopardized vital research efforts that could lead to significant biomedical breakthroughs. They shared alarming reports of researchers scaling back their projects and being unable to compensate graduate students, prompting many early-career scientists to consider opportunities overseas, particularly in China and Europe, which are actively seeking top talent. In response to the mounting concerns, Bhattacharya appeared unfazed, asserting, "We didn’t cut any funding," and insisted that the United States remains the premier location globally for biomedical research. His remarks, however, did little to alleviate the worries surrounding the future of medical research and patient care in the country.